First Time Loading...

Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.97 EUR -1.98% Market Closed
Updated: Apr 28, 2024

Wall Street
Price Targets

HPHA Price Targets Summary
Heidelberg Pharma AG

Wall Street analysts forecast HPHA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HPHA is 11.53 EUR with a low forecast of 11.41 EUR and a high forecast of 11.87 EUR.

Lowest
Price Target
11.41 EUR
284% Upside
Average
Price Target
11.53 EUR
288% Upside
Highest
Price Target
11.87 EUR
299% Upside
Heidelberg Pharma AG Competitors:
Price Targets
CRIS
Curis Inc
53% Upside
ABIO
ARCA Biopharma Inc
96% Upside
IONS
Ionis Pharmaceuticals Inc
36% Upside
214450
PharmaResearch Co Ltd
47% Upside
APGE
Apogee Therapeutics Inc
86% Upside
SWTX
SpringWorks Therapeutics Inc
50% Upside
CBUS
Cibus Inc
48% Upside
VITR
Vitrolife AB
51% Upside

Revenue
Forecast

Revenue Estimate
Heidelberg Pharma AG

For the last 7 years the compound annual growth rate for Heidelberg Pharma AG's revenue is 33%. The projected CAGR for the next 2 years is 25%.

33%
Past Growth
25%
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Heidelberg Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Heidelberg Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HPHA's stock price target?
Price Target
11.53 EUR

According to Wall Street analysts, the average 1-year price target for HPHA is 11.53 EUR with a low forecast of 11.41 EUR and a high forecast of 11.87 EUR.

What is Heidelberg Pharma AG's Revenue forecast?
Projected CAGR
25%

For the last 7 years the compound annual growth rate for Heidelberg Pharma AG's revenue is 33%. The projected CAGR for the next 2 years is 25%.